Sam Backenroth's most recent trade in Vascular Biogenics Ltd was a trade of 525,000 Ordinary Shares done . Disclosure was reported to the exchange on March 31, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vascular Biogenics Ltd | Sam Backenroth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 525,000 | 525,000 (1%) | 1% | - | Ordinary Shares | |
| Vascular Biogenics Ltd | Sam Backenroth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 525,000 | 175,000 | - | - | Restricted Stock Units | |
| NeuBase Therapeutics Inc | Sam Backenroth | CFO, Treasurer & Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2020 | 41,915 | 41,915 | - | - | Stock option (right to buy) |